Jan B Vermorken
Overview
Explore the profile of Jan B Vermorken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
180
Citations
6063
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Limkin E, Blanchard P, Lacas B, Bourhis J, Parmar M, Licitra L, et al.
Radiother Oncol
. 2023 Nov;
190:110011.
PMID: 37956890
Background: A single institution retrospective study suggested that head and neck squamous cell cancer (HNSCC) patients receiving radiotherapy (RT) during "dark" season (fall/winter) may have better outcomes than those treated...
2.
3.
4.
Saba N, Pamulapati S, Patel B, Mody M, Strojan P, Takes R, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046621
Head and neck cancer (HNC) is the seventh most common malignancy, with oropharyngeal squamous cell carcinoma (OPSCC) accounting for a majority of cases in the western world. While HNC accounts...
5.
Cossu Rocca M, Lorini L, Szturz P, Bossi P, Vermorken J
Drugs Aging
. 2023 Jan;
40(2):135-143.
PMID: 36715829
Head and neck cancer is a broad family of diseases, most of which are of squamous cell origin, affecting the epithelial mucosa lining the upper aerodigestive tract. They often recur...
6.
Szturz P, Bonomo P, Vermorken J
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612215
To delineate a patient group with few distant metastases that could possibly benefit from a curative therapeutic strategy employing a local approach, the term oligometastatic disease (OMD) was introduced into...
7.
Domen A, Deben C, De Pauw I, Hermans C, Lambrechts H, Verswyvel J, et al.
Transl Lung Cancer Res
. 2022 Sep;
11(8):1526-1539.
PMID: 36090630
Background: Cure and long-term survival for non-small cell lung cancer (NSCLC) remains hard to achieve. Cellular senescence, an emerging hallmark of cancer, is considered as an endogenous tumor suppressor mechanism....
8.
Shuman A, Aapro M, Anderson B, Arbour K, Barata P, Bardia A, et al.
Oncologist
. 2022 Aug;
PMID: 35962750
No abstract available.
9.
Szturz P, Vermorken J
Br J Cancer
. 2022 Jun;
127(4):587-591.
PMID: 35715637
Allowing selected patients with few distant metastases to undergo potentially curative local ablation, the designation "oligometastatic" has become a widely popular concept in oncology. However, accumulating evidence suggests that many...
10.
de Bree R, Meerkerk C, Halmos G, Makitie A, Homma A, Rodrigo J, et al.
Front Oncol
. 2022 Jun;
12:884988.
PMID: 35651790
In head and neck cancer (HNC) there is a need for more personalized treatment based on risk assessment for treatment related adverse events (i.e. toxicities and complications), expected survival and...